The Latest Breaking News from Biogen

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

We often hear about dementia breakthroughs in the news – new genes being discovered, new blood tests being developed, new drugs being tested.